

Patent number:

WO9301281

Publication date:

1993-01-21

Inventor:

MULLEN CRAIG A [US]; BLAESE R MICHAEL [US]

Applicant:

US HEALTH [US]

Classification:

- international: A01N45/00; A01N63/00; A61K31/75; A61K37/00;

C07H15/12; C07H17/00; C12N15/00; C12Q1/68

- european:

A61K48/00; C12N9/78

Application number: WO1992US05385 19920630 Priority number(s): US19910725076 19910703

Also published as:

図 E

EP0595873 (A1)

US5358866 (A1)

EP0595873 (A4)

EP0595873 (B1)

Abstract of WO9301281

The present invention relates to a system comprising a modified bacterial gene for cytosine deaminase that has been engineered into a eukaryotic expression vector and the expression of the gene by murine fibroblasts. The present invention further relates to methods, gene therapies and vaccines that employ the negative selectable marker, cytosine deaminase, which has the ability to produce a toxic antimetabolite 5-fluorouracil from 5-fluorocytosine.

Data supplied from the esp@cenet database - Worldwide